We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.39% | 2.19 | 2.10 | 2.19 | 2.19 | 2.11 | 2.11 | 1,102,511 | 12:05:34 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.92 | 7.3M |
TIDMIMM TIDMAV.
RNS Number : 9558Z
Immupharma PLC
20 March 2017
20 MARCH 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
TR1 NOTIFICATION OF MAJOR INTEREST
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has today received a TR-1 by Aviva plc ("Aviva"). Aviva's holding in ImmuPharma is now confirmed at a total of 10,280,516 Ordinary Shares which equates to a current position in the Company of 7.76% of ImmuPharma's total voting rights figure of 132,522,985 Ordinary Shares.
Full disclosure of the TR1 is shown below:
1. Identity of the issuer or Immupharma plc the underlying issuer of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ------------------------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ------------------------------------------------------------------------------------------------------------ An acquisition or disposal of voting rights ---------------------------------------------------------------------------------------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ---------------------------------------------------------------------------------------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ---------------------------------------------------------------------------------------------------------- An event changing the breakdown of voting rights ---------------------------------------------------------------------------------------------------------- Other (please specify): CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING ----------------------------------------------------------- --------------------------------------------- 3. Full name of person(s) Aviva plc & its subsidiaries subject to the notification obligation: (iii) ------------------------------------------------------------- --------------------------------------------- 4. Full name of shareholder(s) Registered Holder: (if different from 3.):(iv) Chase (GA Group) Nominees Limited : 7,361,243* HSBC Global Custody Nominee (UK) Limited : 1,606,013* State Street Nominees Limited : 200,974* *denotes direct interest Chase (GA Group) Nominees Limited : 409,378 Chase Nominees Limited : 248,294 Vidacos Nominees Limited : 436,614 ------------------------------------------------------------- --------------------------------------------- 5. Date of the transaction 16 March 2017 and date on which the threshold is crossed or reached: (v) ------------------------------------------------------------- --------------------------------------------- 6. Date on which issuer 17 March 2017 notified: ------------------------------------------------------------- --------------------------------------------- 7. Threshold(s) that is/are 7% to 6% Change at Direct crossed or Interest Level (Box 8A) reached: (vi, vii) ------------------------------------------------------------- --------------------------------------------- 8. Notified details: -------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) -------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after of to the triggering the triggering transaction shares transaction if possible using the ISIN CODE ------------------- -------------------------------- ------------------------------------------------------- Number Number Number Number of % of voting of of of voting rights (x) Shares Voting shares rights Rights ------------------- ------------------- ----------- ----------- ---------------------- ------------------ Direct Direct Indirect Direct Indirect (xi) (xii) ------------------- ------------------- ----------- ----------- ---------- ---------- ------- --------- Ordinary Shares GB0033711010 11,169,942 11,169,942 10,262,516 9,168,230 1,094,286 6.92% 0.83% ------------------- ----------- ----------- ---------- ---------- ------- --------- B: Qualifying Financial Instruments -------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------- Type of financial Expiration Exercise/ Number of voting % of voting instrument date Conversion rights that rights (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ------------------- ------------------- ------------------------ ---------------------- ------------------ 18,000* RIGHT TO RECALL LOANED SHARES N/A N/A *DIRECT INTEREST 0.01% ------------------- ------------------- ------------------------ ---------------------- ------------------ C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ----------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ----------------------------------------------------------------------------------------------- Type of financial Exercise Expiration Exercise/ Number of voting % of voting instrument price date Conversion rights instrument rights (xix, (xvii) period refers to xx) (xviii) ------------------ --------- ----------- ------------ ------------------- ---------------- Total (A+B+C) ------------------------------------------------------ Number of voting rights Percentage of voting rights ------------------------ ---------------------------- 10,280,516 7.76% ------------------------ ---------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) -------------------------------------------------------------------------------- The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: * Aviva plc (Parent Company) * Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) * Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) * Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited) Proxy Voting: --------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4 --------------------------------------------- --------------------------------- 11. Number of voting rights proxy holder will cease to hold: --------------------------------------------- --------------------------------- 12. Date on which proxy holder will cease to hold voting rights: --------------------------------------------- --------------------------------- 13. Additional information: Figures are based the revised total number of voting rights of 132,522,985 as per the recent GBP4.1 Million Fund Raise via Accelerated Bookbuild announcement of 10 March 2017. --------------------------------------------- --------------------------------- 14. Contact name: Neil Whittaker, Aviva plc --------------------------------------------- --------------------------------- 15. Contact telephone number: 01603 684420 --------------------------------------------- ---------------------------------
-Ends-
For further information please contact: + 44 (0) 20 ImmuPharma plc (www.immupharma.org) 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 Twitter: @immupharma 413496 Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance +44 (0)20 3861 Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLFBLFLDXFXBBV
(END) Dow Jones Newswires
March 20, 2017 07:41 ET (11:41 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions